Zepbound 2.5 mg/.5mL (Tirzepatide INJECTION, SOLUTION) 2.5 mg/.5mL

Zepbound acts on incretin pathways involved in appetite regulation and glucose control.

• Chronic weight management in adults with obesity: supports long-term treatment in eligible adults when used under prescriber supervision.
• Chronic weight management in adults with overweight: supports treatment in adults with overweight when prescribed with appropriate clinical assessment.
• Weight-related risk reduction: used in adults for chronic management of excess body weight in line with approved labeling and clinical selection criteria.

• Tirzepatide is a dual agonist at glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. By activating both incretin pathways, it increases glucose-dependent insulin secretion, lowers glucagon secretion, slows gastric emptying, and reduces appetite. These combined effects support reduced energy intake and changes in metabolic regulation relevant to chronic weight management.

Zepbound can cause adverse effects, and the profile should be reviewed in the prescribing information before use.

Common Side Effects

• Nausea: a frequently reported gastrointestinal reaction.
• Diarrhea: may occur during treatment.
• Vomiting: can happen, especially during dose changes.
• Constipation: reported as a common digestive effect.
• Abdominal pain: discomfort or pain in the stomach area may occur.
• Decreased appetite: reduced hunger is a known effect and may be accompanied by poor tolerance.

Serious or Rare Side Effects

• Pancreatitis: severe persistent abdominal pain requires urgent evaluation.
• Gallbladder problems: gallstones or gallbladder inflammation may occur.
• Hypersensitivity reactions: serious allergic reactions can include swelling or breathing difficulty.
• Kidney injury: dehydration from gastrointestinal symptoms may worsen renal function.
• Hypoglycemia: risk may increase when combined with other glucose-lowering medicines.

Before use, review key safety points from the product labeling.

• Prescriber assessment: confirm the indication and review the full medical history before treatment.
• Pancreatitis history: use caution if there is a prior history of pancreatitis.
• Gallbladder disease: monitor patients with a history of gallbladder disorders.
• Renal risk: dehydration from gastrointestinal adverse effects can contribute to kidney problems.
• Allergy history: do not use if there is known hypersensitivity to tirzepatide or any component.
• Store at 2-8°C: keep refrigerated in the original carton, protect from light, and do not freeze or shake.

Zepbound may interact with other medicines that affect glucose control or drug absorption.

Major Interactions (Avoid)

• Other tirzepatide-containing products: do not combine with duplicate therapy.
• Severe hypersensitivity triggers: avoid re-exposure if prior serious allergy to the product has occurred.

Moderate Interactions (Monitor Closely)

• Insulin: combined use can increase hypoglycemia risk.
• Sulfonylureas: glucose monitoring may be needed if used together.
• Oral medications with narrow timing needs: delayed gastric emptying may affect absorption.
• Other diabetes medicines: treatment plans may need monitoring for glucose effects.